Skip to main content
Premium Trial:

Request an Annual Quote

Spotfire Sells DecisionSite Platform to Microbia

NEW YORK, April 12 - Spotfire is expected to announce on Monday that privately held biotech company Microbia has bought its DecisionSite software to help its anti-infective drug-discovery research.

Microbia will integrate the Spotfire software with its Oracle-based application SCOPE, which stores biological-screening data, and with MDL Information Systems' ISIS Host, which stores the chemical properties of select compounds.

"We're building an advanced drug-discovery platform around our SCOPE system," said Kevin Durfee, Microbia's director of IT. "Spotfire is a critical piece of that system and provides a strategic advantage for our company."

Financial terms of the deal were not disclosed.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.